Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Discovery of Clinically Used Octenidine as NRAS Repressor That Effectively Inhibits NRAS-Mutant Melanoma.

Journal of medicinal chemistry - 13 Apr 2023

Chen Xiu-Cai, Tang Gui-Xue, Dai Jing, Dai Le-Tian, Wu Tian-Ying, Li Wen-Wei, Ou Tian-Miao, Huang Zhi-Shu, Tan Jia-Heng, Chen Shuo-Bin

Abstract excerpt

Mutations in NRAS promote tumorigenesis and drug resistance. As this protein is often considered an undruggable target, it is urgent to develop novel strategies to suppress NRAS for anticancer therapy. Recent reports indicated that a G-quadruplex (G4) structure formed in the untranslated region of NRAS mRNA can downregulate NRAS translation, suggesting a potential NRAS suppression strategy. Here, we developed a...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cell Line, Tumor
Share to GTP Phosphohydrolases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Melanoma

Share to Membrane Proteins

Share to Mutation

Share to Phosphatidylinositol 3-Kinases

Share to Skin Neoplasms

Source

Identifiers

PMID: 36961300
DOI: 10.1021/acs.jmedchem.3c00094

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Discovery of Clinically Used Octenidine as NRAS Repressor That Effectively Inhibits NRAS-Mutant Melanoma.PMID 36961300Read ↗

MicroRNA-708 emerges as a potential candidate to target undruggable NRAS.Semantic proximity Read ↗

Oncogenic NRAS has multiple effects on the malignant phenotype of human melanoma cells cultured in vitro.Semantic proximity Read ↗

Identification of ARHGEF17, DENND2D, FGFR3, and RB1 mutations in melanoma by inhibition of nonsense-mediated mRNA decay.Semantic proximity Read ↗

The long non-coding RNA <i>SAMMSON</i> is essential for uveal melanoma cell survivalSemantic proximity Read ↗

Targeting NRAS-Mutant Cancers with the Selective STK19 Kinase Inhibitor Chelidonine.Semantic proximity Read ↗

Targeting NRAS in melanoma.Semantic proximity Read ↗

Acyl protein thioesterase 1 and 2 (APT-1, APT-2) inhibitors palmostatin B, ML348 and ML349 have different effects on NRAS mutant melanoma cells.Semantic proximity Read ↗

Inhibition and degradation of NRAS with a pan-NRAS monobody.Semantic proximity Read ↗

A novel combination treatment against melanoma with NRAS mutation and therapy resistance.Semantic proximity Read ↗

Research in practice: Therapeutic targeting of oncogenic GNAQ mutations in uveal melanoma.Semantic proximity Read ↗

Peptide nucleic acid conjugates regulate gene expression in vitro : mode of action and new strategies for improved cellular uptakeSemantic proximity Read ↗

G-Quadruplex targeting ligands: A hope and a new horizon in Cancer TherapeuticsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.